AstraZeneca (LON:AZN) Shares Up 7% – What’s Next?

AstraZeneca PLC (LON:AZN)’s share price shot up 7% during mid-day trading on Friday. The stock traded as high as £139.96 and last traded at £139.66. Approximately 40,195,961 shares changed hands during trading, an increase of 35% from the average session volume of 29,693,102 shares. The stock had previously closed at £130.52.

Key Stories Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Revenue rose 7% to $16.21 billion, while quarterly profit increased and EPS more than doubled Wall Street’s estimate. The performance suggests AstraZeneca is successfully managing pressure from generic competition to Farxiga. AstraZeneca Q3 2026 Earnings
• Positive Sentiment: Full-year outlook maintained: Management reaffirmed its fiscal 2026 revenue and core EPS guidance at constant exchange rates, easing concerns that generic erosion or other market pressures could force a downgrade. AstraZeneca Q3 Profit and Guidance
• Positive Sentiment: Pipeline investment and cost savings: AstraZeneca launched a $1.5 billion savings program, with the proceeds intended to support drug development. The CEO also highlighted more than $20 billion in potential from 2027 clinical-trial readouts, strengthening the longer-term growth narrative. AstraZeneca Savings Drive
• Positive Sentiment: Oncology momentum: A Tagrisso combination produced a significant survival benefit in a lung-cancer trial, adding support for AstraZeneca’s key cancer franchise. Tagrisso Lung Cancer Trial
• Positive Sentiment: Analyst support: Jefferies reaffirmed its “buy” rating and set a £175 price target, above recent trading levels, reinforcing bullish sentiment. Jefferies AstraZeneca Recommendation
• Negative Sentiment: Generic competition affecting Farxiga remains a headwind, although stronger cancer-drug sales and the reaffirmed outlook currently appear to be offsetting the risk. AstraZeneca Cancer Drugs and Farxiga

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on AZN shares. Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research report on Tuesday, September 29th. Royal Bank Of Canada started coverage on AstraZeneca in a research note on Tuesday, September 8th. They issued an “outperform” rating and a £145 target price for the company. Jefferies Financial Group reiterated a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Friday. Finally, Berenberg Bank restated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research note on Wednesday, October 7th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of £153.57.

AstraZeneca Price Performance

The firm has a 50-day moving average of £122.69 and a 200-day moving average of £134.30. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The stock has a market cap of £217.06 billion, a PE ratio of 20.95, a PEG ratio of 0.86 and a beta of 0.21.

Insider Activity

In other news, insider Michel Demare bought 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of £121.21 per share, with a total value of £303,025. Company insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.